The FDA last week granted a fast-tracked review to ...

...Eli Lilly and Boehringer Ingelheim's Jardiance for the treatment of chronic kidney disease. Jardiance, an SGLT2 inhibitor, is currently approved for the treatment of type 2 diabetes, and holds preferred formulary status for 50% of all covered lives, growing to 90% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 3/16/20